Clinical Trials List
2018-02-05 - 2022-12-31
Phase II
Terminated9
ICD-10C67
Malignant neoplasm of bladder
ICD-9233.9
Carcinoma in situ of other and unspecified urinary organs
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 裘坤元 Division of Urology
- Chia-Yen Lin Division of Urology
- 熊小澐 Division of Radiology
- Chuan-Shu Chen Division of Urology
- 洪晟鈞 Division of Urology
- Cheng-Che Chen Division of Urology
- Shian-Shiang Wang Division of Urology
- 王樹吉 Division of Urology
- Cheng-Kuang Yang Division of Urology
- 盧嘉文 Division of Urology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Wu-Chou Su Division of Hematology & Oncology
- Jiann-Hui Ou Division of Urology
- Shang-Yin Wu Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
- Wei-Pang Chung Division of Hematology & Oncology
- Yuh-Shyan Tsai Division of Urology
- Ya-Ting Hsu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Audit
None
Co-Principal Investigator
- 饒坤銘 Division of Hematology & Oncology
- 劉建廷 Division of Hematology & Oncology
- Shau-Hsuan Li Division of Hematology & Oncology
- 吳佳哲 Division of Hematology & Oncology
- 陳彥仰 Division of Hematology & Oncology
- 陳彥豪 Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- Meng-Jer Hsieh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Wei-Ching Lin Division of Radiology
- Chi-Rei Yang Division of Urology
- Ming-Hung Tsai Division of Hematology & Oncology
- Chi-Ping Huang Division of Urology
- Che-Hung Lin Division of Hematology & Oncology
- Chao-Hsiang Chang Division of Urology
- Chi-Ching Chen Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- - - Division of Urology
- Chia-Chi Lin Division of Hematology & Oncology
- Yeong-Shiau Pu Division of Urology
- YU-CHUAN LU Division of Urology
- Ying-Chun Shen Division of Hematology & Oncology
- CHUNG-HSIN CHEN Division of Urology
- JHE-CYUAN GUO Division of Hematology & Oncology
- - - Division of Urology
- 洪士鈞 Division of Urology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Audit
None
Co-Principal Investigator
- 黃俊農 Division of Urology
- Wei-Ming Li Division of Urology
- Tsung-Yi Huang Division of Urology
- Ching-Chia Li Division of Urology
- Hsiang Ying Lee Division of Urology
- Shu-Pin Huang Division of Urology
- Hsin-Chih Yeh Division of Urology
- Sheng-Chen Wen Division of Urology
- Hung-Lung Ke Division of Urology
- Yung-Chin Lee Division of Urology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Hsiao-Jen Chung Division of Urology
- Chueh-Chuan Yen Division of Hematology & Oncology
- Tzu-Hao Huang Division of Urology
- 潘競成 Division of Others
- Mu-Hsin Chang Division of Hematology & Oncology
- 沈書慧 Division of Radiology
- Yi-Hsiu Huang Division of Urology
- Tzeon-jye Chiou Division of Hematology & Oncology
- Tzu-Ping Lin Division of Urology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Su-Peng Yeh 未分科
Audit
None
Co-Principal Investigator
- Rita cheng Division of Hematology & Oncology
- Yung-Chia Kao Division of Hematology & Oncology
- Kai-Jie Yu Division of Hematology & Oncology
- Hong-Cheng Gan Division of Hematology & Oncology
- 張英勛 Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- I-hung Shao Division of Hematology & Oncology
- 劉忠一 Division of Hematology & Oncology
- Cheng-Lung Hsu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
3 Stop recruiting
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
125 participants
-
Global
375 participants